{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:35:43Z","timestamp":1794353743370,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["c4008-23w"],"award-info":[{"award-number":["c4008-23w"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    N\n                    <jats:sup>6<\/jats:sup>\n                    -methyladenosine (m\n                    <jats:sup>6<\/jats:sup>\n                    A) modification of mRNAs is a predominant epigenetic regulatory mechanism in tumor initiation and progression. Cancer stem cells (CSCs) are the key drivers of colorectal cancer (CRC) initiation and chemotherapy resistance. Here, we found that the m\n                    <jats:sup>6<\/jats:sup>\n                    A reader YT521-B homologous domain family, member 1 (YTHDF1), promotes CRC stemness, tumorigenesis, and chemotherapy resistance. YTHDF1 protein expression was positively correlated with CD133 and LGR5 expression in human CRC tissues (N\u2009=\u2009184,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001 for both markers). YTHDF1 promoted m\n                    <jats:sup>6<\/jats:sup>\n                    A-dependent self-renewal in CSCs and patient-derived organoids and increased the tumor-initiating potential in vivo. Lgr5-specific\n                    <jats:italic>Ythdf1<\/jats:italic>\n                    -KI mice presented accelerated\n                    <jats:italic>Apc<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>Min\/+<\/jats:italic>\n                    <\/jats:sup>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and AOM\/DSS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05)-induced colorectal tumorigenesis, whereas Lgr5-specific\n                    <jats:italic>Ythdf1<\/jats:italic>\n                    knockout in\n                    <jats:italic>Apc<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>Min\/+<\/jats:italic>\n                    <\/jats:sup>\n                    mice inhibited tumorigenesis (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01). Integrative multiomic profiling revealed NOTCH1 as a downstream target. YTHDF1 binds m\n                    <jats:sup>6<\/jats:sup>\n                    A-modified\n                    <jats:italic>NOTCH1<\/jats:italic>\n                    , promoting its translation and enhancing NOTCH signaling. NOTCH1 knockdown or blockade by the \u03b3-secretase inhibitor DAPT abolished YTHDF1-mediated tumorigenesis in\n                    <jats:italic>Ythdf1<\/jats:italic>\n                    knock-in mice (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01). YTHDF1 promoted resistance to oxaliplatin and 5-fluorouracil in CSCs by inhibiting apoptosis and DNA damage. AOM\/DSS-treated\n                    <jats:italic>Ythdf1<\/jats:italic>\n                    knock-in mice presented increased resistance to oxaliplatin (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 5-fluorouracil (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). Translationally, in vivo targeting of YTHDF1 via VNP-encapsulated si\n                    <jats:italic>YTHDF1<\/jats:italic>\n                    or salvianolic acid C inhibited tumor growth (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05 for both treatments) and increased treatment efficacy when VNP was combined with oxaliplatin (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05, SAC:\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) or 5-fluorouracil (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05 for both treatments). In conclusion, YTHDF1 promotes stemness and chemoresistance in CRC via NOTCH1 activation. Targeting YTHDF1 is a promising strategy to improve the outcome of chemotherapy in CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02507-1","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:02:09Z","timestamp":1766361729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-4999","authenticated-orcid":false,"given":"Henley","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2192-1864","authenticated-orcid":false,"given":"Huarong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1650-0371","authenticated-orcid":false,"given":"Weixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin Ho-Kwan","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-677X","authenticated-orcid":false,"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-3707","authenticated-orcid":false,"given":"Ka-Fai","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-3363","authenticated-orcid":false,"given":"Housheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-3541","authenticated-orcid":false,"given":"Chi Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-2153","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2507_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2507_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/medicina57101108","volume":"57","author":"N Nikolic","year":"2021","unstructured":"Nikolic, N. et al. Prognostic factors for post-recurrence survival in stage II and III colorectal carcinoma patients. Medicina 57, 1108 (2021).","journal-title":"Medicina"},{"key":"2507_CR3","first-page":"133","volume":"18","author":"AI Neugut","year":"2019","unstructured":"Neugut, A. I. et al. FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-Medicare data. Clin. Colorectal Cancer 18, 133\u20131140 (2019).","journal-title":"Clin. Colorectal Cancer"},{"key":"2507_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"key":"2507_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445, 106\u2013110 (2007).","journal-title":"Nature"},{"key":"2507_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50968-6","volume":"9","author":"K Tsunekuni","year":"2019","unstructured":"Tsunekuni, K. et al. CD44\/CD133-positive colorectal cancer stem cells are sensitive to trifluridine exposure. Sci. Rep. 9, 14861 (2019).","journal-title":"Sci. Rep."},{"key":"2507_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature22081","volume":"545","author":"M Shimokawa","year":"2017","unstructured":"Shimokawa, M. et al. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature 545, 187\u2013192 (2017).","journal-title":"Nature"},{"key":"2507_CR8","first-page":"88","volume":"8","author":"GK Dy","year":"2009","unstructured":"Dy, G. K. et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin. Colorectal Cancer 8, 88\u201393 (2009).","journal-title":"Clin. Colorectal Cancer"},{"key":"2507_CR9","doi-asserted-by":"publisher","first-page":"188623","DOI":"10.1016\/j.bbcan.2021.188623","volume":"1876","author":"M Luo","year":"2021","unstructured":"Luo, M., Yang, X., Chen, H. N., Nice, E. C. & Huang, C. Drug resistance in colorectal cancer: an epigenetic overview. Biochim. Biophys. Acta Rev. Cancer 1876, 188623 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2507_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. The role of m6A modification in the biological functions and diseases. Signal Transduct. Target. Ther. 6, 74 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2507_CR11","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.7150\/ijbs.70458","volume":"18","author":"CY Sun","year":"2022","unstructured":"Sun, C. Y., Cao, D., Du, B. B., Chen, C. W. & Liu, D. The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer. Int. J. Biol. Sci. 18, 2744\u20132758 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2507_CR12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1053\/j.gastro.2020.11.013","volume":"160","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. RNA N6-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology 160, 1284\u20131300 (2021).","journal-title":"Gastroenterology"},{"key":"2507_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2021.12.269","volume":"162","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. N6-Methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer. Gastroenterology 162, 1183\u20131196 (2022).","journal-title":"Gastroenterology"},{"key":"2507_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.gastro.2023.04.032","volume":"165","author":"J Zhai","year":"2023","unstructured":"Zhai, J. et al. ALKBH5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy. Gastroenterology 165, 445\u2013462 (2023).","journal-title":"Gastroenterology"},{"key":"2507_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388\u20131399 (2015).","journal-title":"Cell"},{"key":"2507_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/gutjnl-2022-328845","volume":"72","author":"Y Bao","year":"2023","unstructured":"Bao, Y. et al. Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 72, 1497\u20131509 (2023).","journal-title":"Gut"},{"key":"2507_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201949229","volume":"21","author":"B Han","year":"2020","unstructured":"Han, B. et al. YTHDF1-mediated translation amplifies Wnt-driven intestinal stemness. EMBO Rep. 21, e49229 (2020).","journal-title":"EMBO Rep."},{"key":"2507_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.omto.2021.01.001","volume":"20","author":"P Chen","year":"2021","unstructured":"Chen, P. et al. Targeting YTHDF1 effectively resensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol. Ther. Oncolytics 20, 228\u2013239 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2507_CR19","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.18632\/oncotarget.23554","volume":"9","author":"Y Nishizawa","year":"2018","unstructured":"Nishizawa, Y. et al. Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer. Oncotarget 9, 7476\u20137486 (2018).","journal-title":"Oncotarget"},{"key":"2507_CR20","doi-asserted-by":"publisher","first-page":"204173142093340","DOI":"10.1177\/2041731420933407","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. 3D culture technologies of cancer stem cells: promising ex vivo tumor models. J. Tissue Eng. 11, 2041731420933407 (2020).","journal-title":"J. Tissue Eng."},{"key":"2507_CR21","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers, H. Modeling development and disease with organoids. Cell 165, 1586\u20131597 (2016).","journal-title":"Cell"},{"key":"2507_CR22","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1101\/gad.269415.115","volume":"29","author":"S Ke","year":"2015","unstructured":"Ke, S. et al. A majority of m6A residues are in the last exons, allowing the potential for 3\u2019 UTR regulation. Genes Dev. 29, 2037\u20132053 (2015).","journal-title":"Genes Dev."},{"key":"2507_CR23","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/0008-5472.CAN-14-2051","volume":"74","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 74, 6364\u20136374 (2014).","journal-title":"Cancer Res."},{"key":"2507_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13046-017-0507-3","volume":"36","author":"W Xiao","year":"2017","unstructured":"Xiao, W., Gao, Z., Duan, Y., Yuan, W. & Ke, Y. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma. J. Exp. Clin. Cancer Res. 36, 41 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2507_CR25","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.celrep.2016.07.038","volume":"16","author":"M Adamowicz","year":"2016","unstructured":"Adamowicz, M., Vermezovic, J. & d\u2019Adda di Fagagna, F. NOTCH1 inhibits activation of ATM by impairing the formation of an ATM-FOXO3a-KAT5\/Tip60 complex. Cell Rep. 16, 2068\u20132076 (2016).","journal-title":"Cell Rep."},{"key":"2507_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nsmb.3013","volume":"22","author":"J Vermezovic","year":"2015","unstructured":"Vermezovic, J. et al. Notch is a direct negative regulator of the DNA-damage response. Nat. Struct. Mol. Biol. 22, 417\u2013424 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2507_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep26788","volume":"6","author":"CK Ip","year":"2016","unstructured":"Ip, C. K. et al. Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress. Sci. Rep. 6, 26788 (2016).","journal-title":"Sci. Rep."},{"key":"2507_CR28","doi-asserted-by":"publisher","first-page":"883437","DOI":"10.3389\/fonc.2022.883437","volume":"12","author":"K Geevimaan","year":"2022","unstructured":"Geevimaan, K. et al. Patient-derived organoid serves as a platform for personalized chemotherapy in advanced colorectal cancer patients. Front. Oncol. 12, 883437 (2022).","journal-title":"Front. Oncol."},{"key":"2507_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","volume":"9","author":"S Rezvantalab","year":"2018","unstructured":"Rezvantalab, S. et al. PLGA-based nanoparticles in cancer treatment. Front. Pharmacol. 9, 1260 (2018).","journal-title":"Front. Pharmacol."},{"key":"2507_CR30","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1016\/j.molcel.2023.10.028","volume":"83","author":"Z Zou","year":"2023","unstructured":"Zou, Z. et al. FMRP phosphorylation modulates neuronal translation through YTHDF1. Mol. Cell 83, 4304\u20134317 (2023).","journal-title":"Mol. Cell"},{"key":"2507_CR31","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1038\/emboj.2012.166","volume":"31","author":"J Munoz","year":"2012","unstructured":"Munoz, J. et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent \u2018+4\u2019 cell markers. EMBO J. 31, 3079\u20133091 (2012).","journal-title":"EMBO J."},{"key":"2507_CR32","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-09-2557","volume":"70","author":"SS Sikandar","year":"2010","unstructured":"Sikandar, S. S. et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 70, 1469\u20131478 (2010).","journal-title":"Cancer Res."},{"key":"2507_CR33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/jcb.25196","volume":"116","author":"AW Fender","year":"2015","unstructured":"Fender, A. W., Nutter, J. M., Fitzgerald, T. L., Bertrand, F. E. & Sigounas, G. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J. Cell. Biochem. 116, 2517\u20132527 (2015).","journal-title":"J. Cell. Biochem."},{"key":"2507_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2012.12.021","volume":"23","author":"J Lu","year":"2013","unstructured":"Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171\u2013185 (2013).","journal-title":"Cancer Cell"},{"key":"2507_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/stem.254","volume":"28","author":"X Fan","year":"2010","unstructured":"Fan, X. et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28, 5\u201316 (2010).","journal-title":"Stem Cells"},{"key":"2507_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18860-4","volume":"11","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. Jagged1-Notch1-deployed tumor perivascular niche promotes breast cancer stem cell phenotype through Zeb1. Nat. Commun. 11, 5129 (2020).","journal-title":"Nat. Commun."},{"key":"2507_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37301-3","volume":"9","author":"L Mourao","year":"2019","unstructured":"Mourao, L. et al. Lineage tracing of Notch1-expressing cells in intestinal tumors reveals a distinct population of cancer stem cells. Sci. Rep. 9, 888 (2019).","journal-title":"Sci. Rep."},{"key":"2507_CR38","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1073\/pnas.0900427106","volume":"106","author":"S Fre","year":"2009","unstructured":"Fre, S. et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc. Natl. Acad. Sci. USA 106, 6309\u20136314 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2507_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ejca.2012.02.056","volume":"48","author":"JR Strosberg","year":"2012","unstructured":"Strosberg, J. R. et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer 48, 997\u20131003 (2012).","journal-title":"Eur. J. Cancer"},{"key":"2507_CR40","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/2767-9764.CRC-23-0333","volume":"3","author":"GJ Hanna","year":"2023","unstructured":"Hanna, G. J. et al. A phase I study of the pan-Notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors. Cancer Res. Commun. 3, 1853\u20131861 (2023).","journal-title":"Cancer Res. Commun."},{"key":"2507_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.tips.2023.09.011","volume":"44","author":"E Medina","year":"2023","unstructured":"Medina, E., Perez, D. H., Antfolk, D. & Luca, V. C. New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics. Trends Pharmacol. Sci. 44, 934\u2013948 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"2507_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1155\/2013\/983981","volume":"35","author":"WJ Wang","year":"2013","unstructured":"Wang, W. J. et al. Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis. Markers 35, 395\u2013405 (2013).","journal-title":"Dis. Markers"},{"key":"2507_CR43","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/annonc\/mdq776","volume":"22","author":"D Chu","year":"2011","unstructured":"Chu, D. et al. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann. Oncol. 22, 2440\u20132447 (2011).","journal-title":"Ann. Oncol."},{"key":"2507_CR44","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1245\/s10434-009-0655-6","volume":"16","author":"D Chu","year":"2009","unstructured":"Chu, D. et al. Notch2 expression is decreased in colorectal cancer and related to tumor differentiation status. Ann. Surg. Oncol. 16, 3259\u20133266 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"2507_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s43018-024-00727-y","volume":"5","author":"CJ Bergin","year":"2024","unstructured":"Bergin, C. J. et al. The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors. Nat. Cancer 5, 463\u2013480 (2024).","journal-title":"Nat. Cancer"},{"key":"2507_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/0008-5472.CAN-21-1261","volume":"82","author":"C Berlin","year":"2022","unstructured":"Berlin, C. et al. KMT9 controls stemness and growth of colorectal cancer. Cancer Res. 82, 210\u2013220 (2022).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02507-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02507-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02507-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:02:10Z","timestamp":1766361730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02507-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02507-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}